Selumetinib + Placebo + Radioactive Iodine Therapy
Phase 3Terminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Differentiated Thyroid Cancer
Conditions
Differentiated Thyroid Cancer
Trial Timeline
Aug 27, 2013 → Mar 6, 2019
NCT ID
NCT01843062About Selumetinib + Placebo + Radioactive Iodine Therapy
Selumetinib + Placebo + Radioactive Iodine Therapy is a phase 3 stage product being developed by AstraZeneca for Differentiated Thyroid Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01843062. Target conditions include Differentiated Thyroid Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01843062 | Phase 3 | Terminated |
Competing Products
20 competing products in Differentiated Thyroid Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| CAB-AXL-ADC + PD-1 inhibitor | BioAtla | Phase 1/2 | 33 |
| Abemaciclib + Placebo | Eli Lilly | Phase 3 | 77 |
| Lenvatinib + Placebo | Eisai | Phase 3 | 77 |
| Lenvatinib | Eisai | Pre-clinical | 23 |
| Lenvatinib | Eisai | Phase 2 | 52 |
| LENVATINIB | Eisai | Phase 2 | 52 |
| Selpercatinib Monotherapy | Eli Lilly | Phase 2 | 52 |
| Pembrolizumab + Cisplatin + Docetaxel + Carboplatin | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| sunitinib + everolimus + chemotherapies recommended in france | Novartis | Pre-clinical | 23 |
| Everolimus + Sorafenib | Novartis | Phase 2 | 52 |
| Dabrafenib + Trametinib + Trametinib Placebo + Dabrafenib placebo | Novartis | Phase 3 | 77 |
| PDR001 | Novartis | Phase 2 | 52 |
| Everolimus (Afinitor®) | Novartis | Phase 2 | 52 |
| Sacituzumab govitecan | Gilead Sciences | Phase 2 | 51 |
| sunitinib | Pfizer | Approved | 84 |
| Vandetanib (SAR390530) + Placebo | Sanofi | Phase 3 | 76 |
| Thyrogen (thyrotropin alfa for injection) | Sanofi | Phase 3 | 76 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Larotrectinib monotherapy | Bayer | Phase 2 | 49 |